FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期临床研究

FOLFOX4Regimen for Advanced Hepatocellular Carcinoma:Multicenter Phase-Ⅱ Clinical Research

目的就FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期进行临床研究。方法选取我院2012年3月~2013年4月收治的晚期肝细胞癌患者100例,随机分为观察组（50例）和对照组（50例）。对照组行常规TACE术治疗,而观察组在此基础上采用FOLFOX4方案治疗。结果两组近期临床疗效、生存情况和血清AFP水平下降情况等比较,差异具有统计学意义（P〈0.05）。结论对于晚期肝细胞癌患者而言,FOLFOX4方案临床疗效较佳,安全可靠,可以提高患者的生存质量,不会出现较为严重的并发症,值得推广应用。

Objective To evaluate the FOLFOX4 regimen for advanced hepatocellular carcinoma（HCC）treatment in multicenter phase-Ⅱclinical trials.Methods From March 2012 to April 2013,100 cases of patients with advanced hepatocellular carcinoma（HCC）were enrolled for analysis.All patients were randomly divided into two groups,observation group（50cases）and control group（50cases）.The control group received routine treatment,and the observation group was treated on the basis of using FOLFOX4 regimen.Result In patients receiving the FOLFOX4 regimen,the recent clinical curative effect,survival situation,and serum AFP level drops were all much better than conventional treatments,and differences were statistically significant（P〈0.05）.Conclusion For patients with advanced HCC,FOLFOX4 regimen has better clinical curative effect,and is safe and reliable.FOLFOX4 regimen can improve the quality of life without serious complications,and is worthy of popularization and application.